Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Alzheimers Dis ; 65(2): 543-575, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30103320

RESUMO

BACKGROUND: Studies on subjective cognitive impairment (SCI) and neural activation report controversial results. OBJECTIVE: To evaluate the ability to disentangle the differences of visual N170 ERP, generated by facial stimuli (Anger & Fear) as well as the cognitive deterioration of SCI, mild cognitive impairment (MCI), and Alzheimer's disease (AD) compared to healthy controls (HC). METHOD: 57 people took part in this study. Images corresponding to facial stimuli of "Anger" and "Fear" were presented to 12 HC, 14 SCI, 17 MCI and 14 AD participants. EEG data were recorded by using a HD-EEG HydroCel with 256 channels. RESULTS: Results showed that the amplitude of N170 can contribute in distinguishing the SCI group, since statistically significant differences were observed with the HC (p < 0.05) and the MCI group from HC (p < 0.001), as well as AD from HC (p = 0.05) during the processing of facial stimuli. Noticeable differences were also observed in the topographic distribution of the N170 amplitude, while localization analysis by using sLORETA images confirmed the activation of superior, middle-temporal, and frontal lobe brain regions. Finally, in the case of "Fear", SCI and HC demonstrated increased activation in the orbital and inferior frontal gyrus, respectively, MCI in the inferior temporal gyrus, and AD in the lingual gyrus. CONCLUSION: These preliminary findings suggest that the amplitude of N170 elicited after negative facial stimuli could be modulated by the decline related to pathological cognitive aging and can contribute in distinguishing HC from SCI, MCI, and AD.


Assuntos
Encéfalo/fisiopatologia , Disfunção Cognitiva/fisiopatologia , Eletroencefalografia/métodos , Potenciais Evocados Visuais , Reconhecimento Facial/fisiologia , Idoso , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/fisiopatologia , Envelhecimento Cognitivo/fisiologia , Disfunção Cognitiva/diagnóstico , Disfunção Cognitiva/psicologia , Estudos Transversais , Diagnóstico Diferencial , Autoavaliação Diagnóstica , Potenciais Evocados Visuais/fisiologia , Feminino , Humanos , Masculino , Testes Neuropsicológicos , Dados Preliminares , Sensibilidade e Especificidade
2.
Data Brief ; 15: 1048-1056, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29204464

RESUMO

We present a dataset that combines multimodal biosignals and eye tracking information gathered under a human-computer interaction framework. The dataset was developed in the vein of the MAMEM project that aims to endow people with motor disabilities with the ability to edit and author multimedia content through mental commands and gaze activity. The dataset includes EEG, eye-tracking, and physiological (GSR and Heart rate) signals collected from 34 individuals (18 able-bodied and 16 motor-impaired). Data were collected during the interaction with specifically designed interface for web browsing and multimedia content manipulation and during imaginary movement tasks. The presented dataset will contribute towards the development and evaluation of modern human-computer interaction systems that would foster the integration of people with severe motor impairments back into society.

3.
J Alzheimers Dis ; 54(1): 129-33, 2016 07 27.
Artigo em Inglês | MEDLINE | ID: mdl-27472878

RESUMO

There is evidence to suggest the efficacy of Crocus (saffron) in the management of cognitive decline. This study examined the efficacy of Crocus in patients with amnesic and multi domain MCI (aMCImd). The participants included 17 patients on Crocus and 18 on a waiting list, who were examined with a short neuropsychological battery, MRI 3T, while some patients were examined via 256-channel electroencephalogram (HD-EEG) at baseline and after 12 months. The results showed that patients on Crocus had improved Mini-Mental State Examination scores (p = 0.015), while the control group deteriorated. Also, MRI, EEG, and ERP showed improvement in specific domains. This led us to conclude that Crocus is a good choice for management of aMCImd.


Assuntos
Encéfalo/efeitos dos fármacos , Disfunção Cognitiva/tratamento farmacológico , Crocus , Nootrópicos/uso terapêutico , Fitoterapia , Extratos Vegetais/uso terapêutico , Idoso , Encéfalo/diagnóstico por imagem , Encéfalo/fisiopatologia , Disfunção Cognitiva/diagnóstico por imagem , Disfunção Cognitiva/fisiopatologia , Eletroencefalografia , Potenciais Evocados , Feminino , Seguimentos , Humanos , Imageamento por Ressonância Magnética , Masculino , Testes de Estado Mental e Demência , Testes Neuropsicológicos , Nootrópicos/efeitos adversos , Extratos Vegetais/efeitos adversos , Método Simples-Cego , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA